CNTB: Rapid efficacy and strong economic value support phase III plans for acute asthma treatment
Seabreeze asthma study results confirmed rapid, significant lung function improvement and reduced exacerbations, supporting phase III planning and regulatory engagement. Updated U.S. data reveal a larger market and strong health economic value, with both acute and chronic indications validated.Base…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.